Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Incyte Corporation
Novartis envisions the drug, the first oral monotherapy for PNH, as a “pipeline in a pill” that could see $3bn in peak sales, with a Phase III readout in IgAN in October and one in C3G expected this month.
Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.
While the weaker yen boosted the top line for Japanese pharma companies with a strong global presence in the fiscal first half, it also raised reported costs. Several firms reported strong growth for mainstays, while holding out high hopes for selected new drugs with blockbuster potential. But some other products underperformed for unexpected reasons.
Sun Pharma sees all time high market share and prescription trends in the US for key specialty products and remains upbeat on the prospects of deuruxolitinib for alopecia areata. The company also isn’t ruling out a potential comeback, at least not yet, for a higher dose version of the JAK1/2 inhibitor.
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Maxia Pharmaceuticals, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.